Russell Investments Group Ltd. Purchases 92,788 Shares of Abbott Laboratories $ABT

Russell Investments Group Ltd. boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 8.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,218,261 shares of the healthcare product maker’s stock after acquiring an additional 92,788 shares during the period. Russell Investments Group Ltd. owned about 0.07% of Abbott Laboratories worth $163,020,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in shares of Abbott Laboratories during the second quarter valued at approximately $3,026,180,000. Laurel Wealth Advisors LLC lifted its holdings in Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after buying an additional 6,011,891 shares during the period. Vanguard Group Inc. boosted its position in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after acquiring an additional 2,977,715 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of Abbott Laboratories by 180.7% in the 2nd quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after acquiring an additional 1,972,097 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Abbott Laboratories by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after acquiring an additional 1,390,554 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 1.2%

Shares of NYSE:ABT opened at $109.74 on Monday. The business’s 50-day moving average is $116.09 and its 200 day moving average is $124.57. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.15. The firm has a market capitalization of $190.69 billion, a P/E ratio of 29.50, a P/E/G ratio of 1.74 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the company earned $1.34 earnings per share. The company’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. BTIG Research dropped their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Citigroup decreased their price target on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Piper Sandler cut their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Finally, Evercore reduced their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.